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Abstract
Lymphocytes and related cell lines are predominantly CD13-negative, however, there are reports describing neutral
aminopeptidase activity in or on these cells. The aim of this study was to answer the question, whether this activity
originates from APN-gene expression.
 .The total cellular activities Ala-pNA hydrolysis of lymphoid cell lines are up to 15 times higher than that of normal
lymphocytes. Despite weak or lacking CD13 surface expression all lymphoid cell lines tested contain APNmRNA as
quantified by competitive RT-PCR as well as low enzymatic activity in their particulate fractions. By isoelectric focusing
two enzyme species with isoelectric points of 5.4 or between 3.5 to 4.8, respectively, were detected. To investigate whether
these activities result from APN-gene we established transfectants lacking cellular APN expression of the CD13-positive
 .histiocytic cell line U937 and the CD13-negative T cell line H9. Studies on these transfectants proved I that the main
 .neutral aminopeptidase activity expressed in lymphoid cells is definitively not related to APN and II that APN is also
expressed in lymphoid cells, although on a low level only.
 .Keywords: Neutral aminopeptidase; Antisense; CD13; Lymphoid cell; EC 3.4.11.2
1. Introduction
APN is expressed in many tissues including intes-
tine, kidney, liver as well as the central nervous
w xsystem 1,2 . The enzyme is involved in the final
Abbreviations: Ala-b NA, alanine-b-methoxy-naphthylamide;
Ala-pNA, alanine-p-nitroanilide; APN, aminopeptidase N;
HUVE-cells, human umbilical vein endothelial cells; IEF, iso-
electric focusing; IP, isoelectric point; PBS, phosphate buffered
saline; RT, reverse transcription
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hydrolysis of nutrients and the degradation of bioac-
w xtive molecules such as tuftsin and cytokines 3–5 .
Furthermore, APN serves as a receptor for corona
w xviruses 6,7 , and it is possibly involved in processes
w xof antigen presentation 8 . Recently, Saiko and co-
workers have shown that the CD13 antigen is in-
volved in the regulation of tumour-cell invasion and
w xthe degradation of extracellular matrix 9 . In the
diagnostic of hematopoietic malignant disorders APN
is used as a routine marker for myelomonocytic cells
w x3,10 . Other cells such as lymphocytes and related
w xcell lines are predominantly CD13-negative 1,10,11 .
However, there are several reports describing the
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occurrence of neutral aminopeptidase activities in or
on these cells. Amoscato and co-workers reported on
Ala-pNA-hydrolysing activity located on the cell sur-
w xface of lymphoid cell lines 12 . Other reports ex-
tended these findings showing that APN is expressed
on peripheral blood lymphocytes and on lymphoid T
w xcell lines as well 13,14 . It was also shown that the
CD13 antigen is frequently expressed on the surface
w xof malignant B cells 15 , on T lymphocytes derived
w xfrom inflamed tissues 16 as well as on mitogen
w xactivated T cells 17 .
Other reports describe, however, that peripheral
blood lymphocytes, Jurkat T cells and tumour cells
separated from patients suffering from leukeamia ex-
press neutral aminopeptidase activity which is dis-
tinct from APN with respect to its biochemical prop-
erties such as substrate specificity, sensitivity to in-
w xhibitors, or CD13-immunoreactivity 18–20 .
In the studies presented here, we investigated neu-
tral aminopeptidase activity of cell lines to answer
the question, whether this activity originates from the
APN-gene and then would represent a modified APN,
or whether it has to be attributed to another amino-
peptidase.
2. Materials and methods
2.1. Cell cultures
The CD13-positive histiocytic cell line U937-H
and the lymphoid cell lines H9, HuT78, Daudi and
Jurkat were obtained from American Type Culture
 .Collection ATTC, Rockville, MD, USA , the
CD13-negative cell clone U937-L, as well as the
lymphoid cell lines Karpas and PC12 Ichikawa cells
were supplied by the German Collection of Microor-
ganisms and Cell Cultures DSM, Braunschweig,
. Germany . Cells were grown in IMDM GibcoBRL,
.Eggenstein, Germany supplemented with 10% foetal
 .  .calf serum Gibco and 60 Urml penicillin Gibco .
Peripheral T cells were purified by nylon adherence
w xas described by others 32 .
2.2. Isoelectric focusing
Cells were solubilized in 1% n-octyl-b-D-gluco-
 .pyranoside in PBS pH 7.4 , and particulate materials
were sedimented by ultracentrifugation 30 min,
.100 000=g . IEF and capillary blotting were per-
w xformed as previously described 14 . Blots were used
for activity staining of neutral aminopeptidase by
means of the chromogenic substrate Ala-b-methoxy-
 . naphthylamide 5 mgr10 ml and Fast Blue B 10
.  .mgr10 ml in PBS pH 7.4 .
2.3. Enzymatic assay
Neutral aminopeptidase activity was determined in
triplicate by measuring the hydrolysis of the chro-
mogenic substrate Ala-pNA in a photometric assay as
w xdescribed previously 14 . Briefly, cells or subcellular
fractions, respectively, were incubated in 100 ml PBS
 .pH 7.4 containing 2.5 mM Ala-pNA. Reactions
were stopped by adding 0.4 ml 1 M sodium acetate
 .  .pH 4.4 , either immediately control or after 60 min
of incubation at 378C. After centrifugation for 5 min
at 48C, absorption of the cell-free supernatants at 390
nm was determined using a Spekol 21 Carl Zeiss
.Jena .
2.4. Cell fractionation
 .Cells were resuspended in PBS pH 7.4 and soni-
cated using a Vibra cell Sonics and Materials, Dan-
.  .bury, CT, USA at 40 W for 2 min 3=40 s .
Cytosolic and particulate fractions were separated by
 .ultracentrifugation 48C, 100 000=g, 2 h of the
lysate.
2.5. Plasmid construction and transfection
The 2785 bp Hin dIII-fragment of the APNcDNA
 w x.kindly provided by A.T. Look, 29 was ligated into
 .the plasmid pREP4 ITC Biotechnology, Germany .
The resulting plasmids contained the APNcDNA
 .fragment in either antisense pREP4AA or sense
 .pREP4AS orientation. Cells were transfected by
 6electroporation 15 mg plasmid DNA per 4=10
cells; H9: 960 mF, 300 V; U937: 250 mF, 300 V;
.cuvette 0.4 cm, Gene Pulser, Bio-Rad and selected
in medium containing 250 mgrml hygromycin
 .Boehringer Mannheim, Germany . Typically, trans-
fected cell populations were established 4–6 weeks
after electroporation.
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2.6. Immunofluorescence staining of cells
Indirect immunofluorescence staining of cells was
w xperformed as described previously 21 . APN was
detected using monoclonal antibodies My-7, Coulter;
.Leu-M7, Becton Dickenson . For control of non-
specific or Fc-receptor mediated labelling, binding of
irrelevant immunoglobulin was determined. This con-
trol value was set to 2%. Cytofluorimetric analyses
were performed using the EPICS PROFILE II
 .Coulter Electronics .
2.7. Competiti˝e PCR
Competitive PCR was performed as described pre-
w xviously 24 . Briefly, RNA was extracted using
 .‘RNeasy’ kit Qiagen . Five hundred ng total RNA
from cells was mixed with an aliquot of a given
dilution of the standard APN-RNA-fragment, and
transcribed into cDNA by 50 U MML-V reverse
 Xtranscriptase using 1 ng APN-specific primer 5 -gcg-
X.gtagaagcccgccaggtca-3 . An aliquot of the cDNA
mixture was used directly for enzymatic amplifica-
tions which were performed in 30 ml reaction volume
containing 0.5 U ‘Gold-Star’ polymerase Eurogen-
.tec , 0.25 mM dNTP, 2.5 mM MgCl , 0.2 pmol of2
 X Xprimers forward: 5 -gccgtgtgcacaatcatcgcact-3 ; re-
X X.verse: 5 -caccagggagcccttgaggtg-3 and 1= reaction
 . buffer Eurogentec in an Autogene II CLF, Emmer-
.sacker, Germany . Initial denaturation at 948C for 3
min was followed by thirty cycles with denaturation
at 958C for 0.7 min, annealing at 548C for 0.6 min
and elongation at 728C for 1.3 min. The final exten-
sion step was at 728C for 10 min. Electrophoresis of
reaction products as well as calculation of the APN-
mRNA contents was performed as described previ-
w xously 24 .
3. Results
3.1. Neutral aminopeptidase acti˝ity
The neutral aminopeptidase activities of cell lines
were investigated by assaying their capability to hy-
drolyse the chromogenic substrate Ala-pNA. Total
cellular activities measured in the lysate of lymphoid
cell lines were in the range of 23 to 172 pkatr106
cells. In comparison with the corresponding activity
 6 .of peripheral T cells 12 pkatr10 cells , related cell
lines showed substantially higher aminopeptidase ac-
 .tivities Table 1 . The CD13-positive histiocytic cell
line U937-H contained 63 pkatr106 cells Ala-pNA
hydrolysing activity. Surprisingly, some of the
CD13-negative lymphoid cell lines such as the B cell
line Daudi, the T cell lines H9, PC12-Ichikawa, and
the weakly CD13-expressing T cell line Karpas con-
tained higher neutral aminopeptidase activities than
 .U937-H cells Table 1 . The majority of this activity
expressed in lymphoid cells as well as in the CD13-
Table 1
Neutral aminopeptidase activity, APN surface expression and APNmRNA content of different cell lines
Cells Ala-pNA hydrolysing activity Cell surface expression APNmRNA content
6 .  .  .pkatr10 cells range of CD13-positive cells, % pgrmg total RNA
Lysate Particulate fraction
U937-H 63"10 40"2 85–98 47 "9
U937-L 42"13 7"2 1–3 0.5"0.4
Daudi 172"90 18"6 1–2 2.0"0.8
Jurkat 23"10 7"2 1–2 1.9"0.6
H9 85"41 6"4 1–2 6.2"5.6
HuT78 41"19 4"1 1–3 6.5"5.0
PC12 74"19 13"5 1 1.9"1.0
Karpas 105"31 13"4 9–27 12.6"3.9
T cells 12"3 3"1 1–3 2.0"0.9
Enzymatic data represent the means of at least 5 experiments. Cell surface expression was determined by immunofluorescence analysis in
 .three separate experiments using My-7 Coulter as described in Section 2. APNmRNA contents of cell lines and peripheral T cells are
the means of three experiments.
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 . 7Fig. 1. Detection of neutral aminopeptidase activities Ala-b NA-hydrolysis of cell lines and peripheral T cells. Total cell lysate of 10
cells from cell lines U937-H, -L, H9, HuT78, Daudi, Jurkat and peripheral T cells as well as 106 cells from Karpas and PC12-Ichikawa
were isoelectrically focused and blotted. Blots were stained enzymatically as described in Section 2.
negative U937-L cells is located in the soluble frac-
tion. In the case of U937-H cells, 63% of the enzy-
matic activity were detected in the particulate frac-
tion, whereas most other cells contained only small
 .Daudi, PC12-Ichikawa, Karpas or neglectable
amounts Jurkat, H9, HuT78, U937-L, peripheral T
Fig. 2. Immunofluorescence analysis of the U937-H cells, the derived transfectants and U937-L cells. CD13 expression of cells was
 .determined using the anti CD13 monoclonal antibody LeuM7 Becton Dickinson as described in Section 2. Control values are black
filled.
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.cells of Ala-pNA-hydrolysing activity in this frac-
 .tion Table 1 .
Activity-staining of isoelectrically focused cell
lysates using Ala-b NA revealed the presence of dif-
ferent enzyme species. The main enzymatic activity
of U937-H cells represents proteins with isoelectric
 .points between 4.8 and 3.5 Fig. 1 . This activity is
also expressed in the lymphoid cell lines PC12 and
Karpas and at a very low level in the T cell lines
HuT78 and H9 as well as in peripheral T cells Figs.
.1 and 3 . The main neutral aminopeptidase activity of
most lymphoid cells, however, represents an enzyme
 .form with an IP of 5.4 Fig. 1 . Using enriched
particulate and cytosolic fractions of the cell lines
U937-H and H9 for isoelectric focusing it was proven
that the cytosolically located Ala-pNA-hydrolysing
activity is identical to the corresponding activity with
an IP of 5.4 and that the enzyme form with an IP of
4.8 represents membrane-bound APN data not
.shown .
3.2. Detection of APN surface expression and APN-
mRNA
The cell surface expression of cell lines was mea-
sured using anti-CD13 monoclonal antibodies. The
level of cell surface expression mainly corresponded
to the presence of Ala-pNA-hydrolysing activity de-
tected in particulate fractions. Strong CD13-surface
expression was found on the histiocytic cell line
U937-H only, and to some lower extent on the T cell
line Karpas, expressing Ala-pNA hydrolysing activity
of 40 pkatr106 cells or 13 pkatr106 cells in their
 .particulate fractions, respectively Table 1 . Although
Daudi and PC12 express activities comparable to that
Karpas cells, both cell lines were CD13-negative
 .Table 1 . All other lymphoid cell lines tested as well
as peripheral T cells were negative in immunofluo-
rescence analysis and contain only neglectable
amounts of enzymatic activity in the particulate frac-
 .tion Table 1 .
To investigate whether the neutral aminopeptidase
activity detected in the soluble fraction of lymphoid
cells results from APN-gene expression, we quanti-
fied APNmRNA contents by competitive PCR Table
.1 . The CD13-positive U937-H cells contained 47 pg
APN-transcript per mg total RNA, whereas 13 pg
APN-transcript per mg total RNA were determined in
the T cell line Karpas, which expresses CD13 at a
lower level than U937-H cells. The APN-transcript
levels of the T cell lines H9 and HuT78 were 6 or 7
pg per mg total RNA, respectively, whereas corre-
Fig. 3. Isoelectric focusing and detection of Ala-b NA hydrolysing activity from the cell lines H9 and U937 as well as from the derived
 .  .transfectants. The pattern of the wildtype H9 cells was identical to that of the H9.2 cells not shown . Used cells: H9.13 antisense , H9.2
 . 7  . 6  .  . 6 sense : 10 cells; U937 lanes B wildtype: 5=10 cells, U937.16 antisense , U937.18 sense : 2=10 cells lanes A represent 1r4 of
.the cells used in lanes B .
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sponding values of all other cells are in the range
from 0.5 to 2 pg APN-transcript per mg RNA.
3.3. Antisense-mediated inhibition of APN-gene ex-
pression
Two plasmids were constructed containing a 2.8
 .kb APNcDNA-insert in either antisense pREP4AA
 .or sense pREP4AS orientation under the control of
the RSV-LTR. Both variants were used to transfect
the cell lines H9 and U937-H. Both the presence of
the plasmids and the transcription of the inserted
APN fragment in the transfectants antisense: H9.13
.and U937.16; sense: H9.2, U937.18 were confirmed
 .by in situ-hybridization data not shown .
The inhibition of the cellular APN expression in
the U937-H transfectants was shown by indirect im-
munofluorescence analyses. The antisense transfec-
tants U937.16 show a marked decrease of their
CD13-immunoreactivity compared to wildtype cells
 .or sense transfectants U937.18 Fig. 2 . Furthermore,
loss of the APN-derived enzymatic activity could be
demonstrated using IEF analysis. The Ala-b NA hy-
drolysing activities with IPs between 3.6-4.8 were
completely absent in antisense transfectants U937.16
 .Fig. 3 . On the contrary, these activities are still
 .present in the U937 wildtype cells as well as in the
 .sense transfectants U937.18 Fig. 3 . Furthermore,
IEF analyses revealed that the antisense H9 cells
 .H9.13 also completely lacked their minor Ala-b NA
hydrolysing activity with an IP 4.8, whereas this
activity was still present in the wildtype cells H9 as
 .well as in the control cells H9.2 Fig. 3 . This result
strongly underlines that the Ala-b NA hydrolysing
activity with an IP of 4.8 which is expressed in H9
cells represents APN. Interestingly, the activity with
an IP of 5.4 is increased in the H9.13 cells. An
induction of this activity was also observed in
 .U937.16 cells Fig. 3 .
4. Discussion
We investigated neutral aminopeptidase activities
of different hematopoietic cell lines. Although APN
expression within the immune system is largely re-
stricted to cells of the myelomonocytic lineage, there
are data providing evidence that lymphoid cells ex-
press APN on their surface after mitogenic activation
w x w x17,25,28 or malignant transformation 15,22 . This
induction of CD13-expression is always accompanied
by an increase of corresponding enzymatic activity
w x17 .
Data presented here show that neutral aminopepti-
dase activities of lymphoid cell lines are 2–15 times
higher compared to peripheral T or B cells, respec-
w xtively 23 . On the contrary, corresponding activities
of the histiocytic cell lines U937-H and -L were
found similar to those determined on normal mono-
w xcytes 23 . Interestingly, with the exception of Karpas
cells enzymatic activities of all lymphoid cell lines
were not accompanied by the appearance of CD13-
immunoreactivity. The absence of CD13-surface ex-
pression correlates with low enzymatic activity de-
tected in the particulate fractions of most lymphoid
cells except Daudi and PC12. At least for Daudi this
fact is due to the higher aminopeptidase activity of
 6 .these cells 172 pkatr10 cells .
To investigate whether high enzymatic activities
located in the soluble fraction are related to APN
expression we studied APN-transcript levels by com-
petitive RT-PCR. The CD13-positive cell line U937-H
contains APN-transcript in amounts comparable to
renal carcinoma cells, which strongly express CD13
w x25 . The APNmRNA-contents of most lymphoid cell
lines studied here are below 7 pgrmg total RNA.
These values are in accordance to data reported from
Riemann and co-workers, who estimated the APN-
mRNA content as 4–6 pgrmg total RNA in the T
 .cell line HuT78 personal information . These low
APN-transcript levels suggest that the considerable
amounts of neutral aminopeptidase activity detected
in the cytosol of lymphoid cell lines could hardly
originate from the APN-gene expression.
The enzymatic pattern of the isoelectric focusing
revealed the presence of two enzyme species which
both represent neutral aminopeptidase activity. As we
showed previously, the species with an IP of 4.8
represents the membrane-bound APN in U937-H cells
w x14 . Although we used different monoclonal antibod-
ies, we did never detect CD13-immunoreactivity of
the enzyme form with an IP of 4.8 in lymphoid cells.
Perhaps, this effect could be explained by the weak
APN expression in lymphoid cells. Recent biochemi-
cal studies using inhibitors and the inhibitory mono-
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clonal anti-CD13 antibody WM15 underlined the dif-
ferent nature of the two neutral aminopeptidase activ-
ities, but they do not definitively answer the question,
whether both enzyme species represent APN. The
detection of additional aminopeptidase activities in
the lymphoid cells is in agreement with data from
w xother groups. Favaloro and co-workers 27 have
shown that only 20–40% of the total neutral amino-
peptidase activity of acute myeloid or lymphoid
leukaemic cells could be attributed to APN. The
authors discussed a high complexity of the protease
expression pattern of the malignant clones. Using the
inhibitory monoclonal antibody WM15 they obtained
quite similar results concerning neutral aminopepti-
w xdase expression of peripheral T cells 20 . Interest-
ingly, Belhacene and co-workers showed that amino-
peptidase B is the main aminopeptidase activity of
w xthe T cell line Jurkat 19 . Furthermore, Murray and
co-workers described an aminopeptidase activity of
Jurkat cells which has to be distinguished from APN
w x18 .
To definitively clarify the possible relation be-
tween the cytosolically located activity detected in
lymphoid cell lines and the APN we established
transfectants lacking cellular APN expression. Func-
tioning of our antisense model was confirmed by
transfecting CD13-positive U937-H cells. The strong
reduction of CD13-immunoreactivity on the antisense
transfectants U937.16 as well as the complete ab-
sence of the enzyme species with IP between 3.5 and
4.8 in these cells demonstrate the capability of our
antisense system to in inhibit cellular APN expres-
sion. Furthermore, the observed variability concern-
 .ing the isoelectric points between 3.5 and 4.8 im-
plies that the APN-derived activity represents more
than one enzyme species. For the first time, the
occurrence of different molecular forms of the APN
was shown in an enzymatic assay. The heterogeneity
observed could be caused by a different extent of
glycosylation as shown by O’Connell and co-workers.
They demonstrated that changes in the glycosylation
pattern of the APN expressed on HUVE-cells create
five APN subpopulations defined by different CD13
w xmonoclonal antibodies 26 .
Until recently, it was assumed that APN expres-
sion within the hematopoietic system is restricted to
w xcells of the myelomonocytic lineage 1,3 . Results
presented here, prove that the Ala-b NA hydrolysing
activity with an IP of 4.8 expressed in H9 cells also
represents APN. On the basis of the IEF analysis it
could be concluded that a small fraction of the cellu-
lar enzymatic activity in H9 cells only could be
attributed to the APN.
The antisense mediated inhibition of the APN
expression clearly demonstrated that the Ala-b-NA
hydrolysing activity with an IP of 5.4 is not due to
APN expression because this activity was not de-
creased in the antisense transfectants derived from
U937-H and H9 cells. Therefore, the high neutral
aminopeptidase activity expressed in H9 cells has to
be attributed to another enzyme. The induction of this
activity observed in the U937-H transfectants could
be considered, perhaps, as a ‘by pass phenomenon’
or ‘compensation’ which is occasionally observed in
w x‘knock out’ experiments 30,31 .
Due to the fact that neutral aminopeptidase activi-
ties of all lymphoid cell lines investigated have bio-
chemical features such as cellular location and iso-
electric point similar to those of the T cell line H9,
we conclude that the main neutral aminopeptidase
activity of all lymphoid cells has to be attributed to
another enzyme which is not related to the well-char-
 .acterised APN EC 3.4.11.2 .
Taken together, the data presented here and our
former results, support the model of a low-level
constitutive APN expression in T cells and related
cell lines which is increased after mitogenic stimula-
tion or malignant transformation as it was demon-
w xstrated by others 13,17,25,28 . This increase is, how-
ever, always associated with the appearance of
CD13-immunoreactivity on the cell surface. How-
ever, besides the APN at least one other cytosolically
located enzyme contributes to the total neutral amino-
peptidase activity in lymphocytes and related cell
lines. This enzyme represents the main neutral
aminopeptidase activity of CD13-negative lymphoid
cell lines. The nature of this Ala-b NA hydrolysing
activity is still unclear.
Preliminary biochemical studies gel chromatogra-
.phy, sensitivity towards inhibitors and metal ions of
this aminopeptidase activity enriched from H9 cells
have revealed that it could be distinguished from
other well-characterised aminopeptidases such as
 .leucine-aminopeptidase EC 3.4.11.1 , cytosolic ala-
 .nine-aminopeptidase EC 3.4.11.14 and puromycin-
sensitive aminopeptidase. Purification and subsequent
( )T. Wex et al.rBiochimica et Biophysica Acta 1355 1997 147–154154
biochemical analyses of this aminopeptidase will be
the next challenge.
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